問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Chang Gung Medical Foundation Chang Gung Memorial Hospital, Keelung (在職)

Digestive System Department

更新時間：2023-09-19

張家昌
  • Co-Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

0Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

張家昌

List

5Cases

2010-07-15 - 2012-06-15

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2011-12-01 - 2016-07-31

Phase II

A Randomised Open-Label Phase IIa Study to Assess the Efficacy and Safety of AZD4547 Monotherapy versus Paclitaxel in Patients with Advanced Gastric or Gastro-oesophageal Junction Cancer with FGFR2 Polysomy or Gene Amplification (Shine study)

  • Condition/Disease

    Advanced Gastric or Gastro-oesophageal Junction Cancer

  • Test Drug

    AZD4547

Participate Sites
7Sites

Terminated6Sites

Study ended1Sites

2015-11-01 - 2018-03-31

Phase III

A Phase 3b Open-Label Study of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 weeks in Subjects with Chronic Genotype 1 or 2 Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) Coinfection

  • Condition/Disease

    Antiviral efficacy of chronic infection with hepatitis C virus (HCV) of genotype 1 or 2

  • Test Drug

    Harvoni®

Participate Sites
15Sites

Terminated14Sites

彭成元
China Medical University Hospital-Taipei

未分科

朱啟仁
Taipei Veterans General Hospital

2012-06-01 - 2014-08-31

Phase I/II

A Phase I/II, Open-label, Randomized, Active Control, Dose Finding Study to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of P1101 in Interferon-Naïve Subjects with Chronic Hepatitis B Virus Infection

  • Condition/Disease

    Hepatitis B virus

  • Test Drug

    P1101

Participate Sites
9Sites

Terminated9Sites

2012-05-01 - 2013-08-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
15Sites

Terminated15Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB